ATORX — Alligator Bioscience AB Share News
0.000.00%
Last trade - 00:00- SEK89.83m
- SEK103.14m
- SEK0.51m
Brief: Alligator Bioscience Receives Additional Subscription Undertakings For Rights Issue
Brief: Alligator Bioscience Announces Final Terms Of Rights Issue
Brief: Alligator Bioscience Gets US Patent Covering Ator-4066 Bispecific Antibody
Brief: Alligator Announces Final 30-Month Optimize-1 Results
Brief: Alligator Bioscience To Receive Approximately SEK 28.1 Mln From Warrants
Brief: Alligator Bioscience: Preliminary Outcome Of Exercise Of Warrants Series TO 13
Brief: Alligator Bioscience, Fenja Agree On Extension Of Loan Maturity
Brief: Alligator Bioscience: Grant Awarded To Phase 2/3 Trial With Mitazalimab In Biliary Tract Cancer
Brief: Alligator Bioscience Q2 Operating Loss Lowers To SEK 22.3 Mln
Brief: Alligator Bioscience Receives Waiver For Paediatric Trials Of Mitazalimab
Brief: Alligator Bioscience Secures 85% Of Warrant Programme TO 12
Brief: Alligator Bioscience Q1 Operating Loss Lowers To SEK 43.7 Mln
Brief: Alligator Bioscience Sets Record Date For Reverse Share Split On April 8
Brief: Alligator Bioscience CMO Leaves
Brief: Alligator Bioscience Announces FDA Orphan Drug Designation For HLX22/AC101
Brief: Alligator Bioscience Announces Continued Overall Survival Benefit For Mitazalimab
Brief: Alligator Bioscience Proposes Reverse Share Split
Brief: Alligator Bioscience Resolved On Directed Issue Of 84,560,000 Units
Brief: Alligator Bioscience To Get SEK 153 Mln From Rights Issue